Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Janux Therapeutics (JANX) Return on Sales (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Return on Sales for 5 consecutive years, with 11.36% as the latest value for Q4 2025.

  • Quarterly Return on Sales fell 485.0% to 11.36% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 11.36% through Dec 2025, down 485.0% year-over-year, with the annual reading at 11.36% for FY2025, 485.0% down from the prior year.
  • Return on Sales for Q4 2025 was 11.36% at Janux Therapeutics, down from 2.43% in the prior quarter.
  • The five-year high for Return on Sales was 0.67% in Q2 2024, with the low at 240.64% in Q2 2025.
  • Average Return on Sales over 5 years is 22.35%, with a median of 8.38% recorded in 2022.
  • Peak annual rise in Return on Sales hit 6148bps in 2025, while the deepest fall reached -23997bps in 2025.
  • Over 5 years, Return on Sales stood at 8.3% in 2021, then soared by 32bps to 5.65% in 2022, then rose by 15bps to 4.78% in 2023, then plummeted by -36bps to 6.52% in 2024, then plummeted by -74bps to 11.36% in 2025.
  • According to Business Quant data, Return on Sales over the past three periods came in at 11.36%, 2.43%, and 240.64% for Q4 2025, Q3 2025, and Q2 2025 respectively.